IDEXX Laboratories, Inc. $IDXX is Kraematon Investment Advisors Inc.’s 10th Largest Position

Kraematon Investment Advisors Inc. lessened its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.0% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,242 shares of the company’s stock after selling 160 shares during the period. IDEXX Laboratories comprises approximately 2.7% of Kraematon Investment Advisors Inc.’s investment portfolio, making the stock its 10th largest holding. Kraematon Investment Advisors Inc.’s holdings in IDEXX Laboratories were worth $2,811,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. MorganRosel Wealth Management LLC acquired a new stake in IDEXX Laboratories during the first quarter valued at $26,000. Opal Wealth Advisors LLC purchased a new stake in shares of IDEXX Laboratories during the 2nd quarter worth about $29,000. Migdal Insurance & Financial Holdings Ltd. grew its position in shares of IDEXX Laboratories by 55.6% during the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company’s stock valued at $35,000 after acquiring an additional 30 shares during the period. Ameritas Advisory Services LLC acquired a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at about $36,000. Finally, WPG Advisers LLC purchased a new position in shares of IDEXX Laboratories in the 1st quarter valued at about $37,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Stock Down 0.4%

Shares of IDXX opened at $631.19 on Friday. The company’s 50-day moving average price is $634.52 and its 200 day moving average price is $535.57. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $688.12. The company has a current ratio of 1.11, a quick ratio of 0.79 and a debt-to-equity ratio of 0.31. The firm has a market cap of $50.50 billion, a P/E ratio of 52.56, a price-to-earnings-growth ratio of 4.09 and a beta of 1.58.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Monday, August 4th. The company reported $3.63 earnings per share for the quarter, beating analysts’ consensus estimates of $3.28 by $0.35. The business had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.06 billion. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The business’s revenue for the quarter was up 10.6% on a year-over-year basis. During the same period last year, the business earned $2.44 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. On average, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on IDXX. Piper Sandler reiterated a “neutral” rating and set a $700.00 price target (up previously from $510.00) on shares of IDEXX Laboratories in a research report on Monday, August 11th. Morgan Stanley increased their target price on IDEXX Laboratories from $722.00 to $765.00 and gave the company an “overweight” rating in a research report on Friday, August 15th. Jefferies Financial Group initiated coverage on shares of IDEXX Laboratories in a report on Tuesday, July 1st. They issued a “buy” rating and a $625.00 price target for the company. UBS Group initiated coverage on shares of IDEXX Laboratories in a research report on Wednesday. They set a “neutral” rating and a $720.00 price objective for the company. Finally, Wall Street Zen downgraded shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Sunday, September 28th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $656.50.

Insider Buying and Selling

In other news, EVP Michael G. Erickson sold 406 shares of IDEXX Laboratories stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $649.96, for a total value of $263,883.76. Following the completion of the sale, the executive vice president directly owned 11,287 shares of the company’s stock, valued at approximately $7,336,098.52. The trade was a 3.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Sharon E. Underberg sold 5,450 shares of the stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $651.60, for a total value of $3,551,220.00. Following the transaction, the executive vice president directly owned 6,156 shares in the company, valued at approximately $4,011,249.60. The trade was a 46.96% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 54,057 shares of company stock valued at $34,293,468 over the last quarter. 0.98% of the stock is owned by corporate insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.